Risk Factors for New Neurologic Diagnoses in Hospitalized Patients With COVID-19: A Case-Control Study in New York City.
Journal
Neurology. Clinical practice
ISSN: 2163-0402
Titre abrégé: Neurol Clin Pract
Pays: United States
ID NLM: 101577149
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
22
02
2022
accepted:
26
04
2022
entrez:
16
11
2022
pubmed:
17
11
2022
medline:
17
11
2022
Statut:
ppublish
Résumé
There have been numerous reports of neurologic manifestations identified in hospitalized patients infected with SARS-CoV-2, the virus that causes COVID-19. Here, we identify the spectrum of associated neurologic symptoms and diagnoses, define the time course of their development, and examine readmission rates and mortality risk posthospitalization in a multiethnic urban cohort. We identify the occurrence of new neurologic diagnoses among patients with laboratory-confirmed SARS-CoV-2 infection in New York City. A retrospective cohort study was performed on 532 cases (hospitalized patients with new neurologic diagnoses within 6 weeks of positive SARS-CoV-2 laboratory results between March 1, 2020, and August 31, 2020). We compare demographic and clinical features of the 532 cases with 532 controls (hospitalized COVID-19 patients without neurologic diagnoses) in a case-control study with one-to-one matching and examine hospital-related data and outcomes of death and readmission up to 6 months after acute hospitalization in a secondary case-only analysis. Among the 532 cases, the most common new neurologic diagnoses included encephalopathy (478, 89.8%), stroke (66, 12.4%), and seizures (38, 7.1%). In the case-control study, cases were more likely than controls to be male (58.6% vs 52.8%, Hospitalized patients with SARS-CoV-2 and new neurologic diagnoses have significant morbidity and mortality postdischarge. Further research is needed to define the effect of neurologic diagnoses during acute hospitalization on longitudinal post-COVID-19-related symptoms including neurocognitive impairment.
Sections du résumé
Background and Objectives
UNASSIGNED
There have been numerous reports of neurologic manifestations identified in hospitalized patients infected with SARS-CoV-2, the virus that causes COVID-19. Here, we identify the spectrum of associated neurologic symptoms and diagnoses, define the time course of their development, and examine readmission rates and mortality risk posthospitalization in a multiethnic urban cohort.
Methods
UNASSIGNED
We identify the occurrence of new neurologic diagnoses among patients with laboratory-confirmed SARS-CoV-2 infection in New York City. A retrospective cohort study was performed on 532 cases (hospitalized patients with new neurologic diagnoses within 6 weeks of positive SARS-CoV-2 laboratory results between March 1, 2020, and August 31, 2020). We compare demographic and clinical features of the 532 cases with 532 controls (hospitalized COVID-19 patients without neurologic diagnoses) in a case-control study with one-to-one matching and examine hospital-related data and outcomes of death and readmission up to 6 months after acute hospitalization in a secondary case-only analysis.
Results
UNASSIGNED
Among the 532 cases, the most common new neurologic diagnoses included encephalopathy (478, 89.8%), stroke (66, 12.4%), and seizures (38, 7.1%). In the case-control study, cases were more likely than controls to be male (58.6% vs 52.8%,
Discussion
UNASSIGNED
Hospitalized patients with SARS-CoV-2 and new neurologic diagnoses have significant morbidity and mortality postdischarge. Further research is needed to define the effect of neurologic diagnoses during acute hospitalization on longitudinal post-COVID-19-related symptoms including neurocognitive impairment.
Identifiants
pubmed: 36382116
doi: 10.1212/CPJ.0000000000200006
pii: CPJ-2022-200006
pmc: PMC9647816
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e66-e74Subventions
Organisme : NIAID NIH HHS
ID : K23 AI150378
Pays : United States
Informations de copyright
© 2022 American Academy of Neurology.
Références
J Alzheimers Dis. 2021;81(2):679-690
pubmed: 33749656
J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):811-812
pubmed: 32503883
Front Neurol. 2020 Oct 30;11:585944
pubmed: 33193048
J Neurol Sci. 2021 Jul 15;426:117486
pubmed: 34000678
JAMA Netw Open. 2020 Nov 2;3(11):e2029540
pubmed: 33211114
Lancet Neurol. 2020 Nov;19(11):919-929
pubmed: 33031735
J Clin Epidemiol. 2002 Aug;55(8):819-24
pubmed: 12384197
Neurology. 2021 Dec 7;97(23):e2269-e2281
pubmed: 34635561
Free Neuropathol. 2021 Jan 18;2:
pubmed: 33554218
BMC Neurol. 2021 Mar 30;21(1):138
pubmed: 33784985
Neurocrit Care. 2021 Dec;35(3):693-706
pubmed: 33725290
MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1695-1699
pubmed: 33180754
Nat Rev Neurol. 2012 Oct;8(10):557-66
pubmed: 22986430
Neurology. 2021 Jan 26;96(4):e575-e586
pubmed: 33020166
Neuropathol Appl Neurobiol. 2021 Feb;47(1):3-16
pubmed: 32935873
Front Neurol. 2021 Feb 19;12:640017
pubmed: 33679593
Neurology. 2021 Mar 16;96(11):e1527-e1538
pubmed: 33443111
Ann Clin Transl Neurol. 2020 Nov;7(11):2221-2230
pubmed: 33016619
Neurosci Lett. 2021 Jan 18;742:135528
pubmed: 33248159
JAMA. 2021 Jan 19;325(3):304-306
pubmed: 33315057
Stroke. 2020 Jul;51(7):2219-2223
pubmed: 32466735
Brain Behav Immun. 2020 Jul;87:149
pubmed: 32387508
MMWR Morb Mortal Wkly Rep. 2020 Nov 20;69(46):1725-1729
pubmed: 33211680